Ligand Pharmaceuticals (LGND) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand Pharmaceuticals (LGND)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Chucky who wrote ()	5/9/1996 8:53:00 AM
From: Henry Niman	of 16

LGND released its 1Q results after the close today. Revenues were at an all time high ($8.8 million) and were almost double 1Q 1995. The increase was due to largely to payments from Alliance Partners AHP, Sankyo, SBE, and ABT. LGND's loss for the quarter ($0.25) beat estimates by $0.02. LGND's report also mentioned the expanded women's health alliance with AHP (their Wyeth Ayerst division licensed anti-progesterone LG1447 and prgesterone agonists LG2527 and LG2716). They also mentioned the settlement of the Droloxifene suit against PFE including their "cash is trash" position and the plan of PFE to enter CP-336,156 into clinical trials in Europe 4Q 1996 and in the U.S. 2Q 1997 for treating osteoporosis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next